3-V is fortunate to have the support of world-class investors, including Kleiner Perkins Caufield & Byers and New Enterprise Associates.
Press Releases
- 3–V Biosciences Presents Positive Preclinical Data on HCV Product Candidates Targeting FASN at the American Association for the Study of Liver Disease Annual Meeting 2012 November 12, 2012
- 3‐V Biosciences To Present Data on HCV Product Candidates at the American Association for the Study of Liver Disease Annual Meeting 2012 October 1, 2012
- 3‐V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference July 10, 2012